In order to highlight the advantages of SmartCells’ SmartInsulin(TM) for treating type 1 diabetes, SmartCells, Inc. and Juvenile Diabetes Research Foundation (JDRF) are going to be partners with a funding of $1 Million.
SmartInsulin is an injectable drug which is specially designed to maintain continuous, tight control of blood glucose levels while reducing the risk of hypoglycemia, like the pancreas does automatically in the absence of diabetes. In other words it is specially designed to act like a pancreas for the body.
SmartInsulin is an once-a-day, glucose-regulated drug which is designed to address the most critical issue in diabetes treatment. It works on the combination of glucose sensing and insulin delivery in a single chemical construct. It can be applied to the treatment of both type 1 and type 2 diabetes. This special injection is injected subcutaneously.
The working method of SmartInsulin consists of an insulin payload attached to a biocompatible, biodegradable polymer, which is bound to an engineered glucose-binding molecule. Insulin is released only when the therapeutic is unbound by the presence of a specific glucose concentration. Once the surrounding glucose concentration drops to a target level, the injected dispersion stops releasing insulin.
The agreement, between JDRF and SmartInsulin is expected to provide $1 million in firstyear funding to support preclinical safety and efficacy testing. The partnership is structured to support milestone-based funding through proof-of-concept human clinical trials.